ARTICLE | Company News
Immunomedics other research news
October 7, 1996 7:00 AM UTC
IMMU received a $100,000 Phase I SBIR grant from NIH to develop an immunoconjugate antibody-targeted drug to treat PCP in AIDS and other conditions of severe immunosuppression. The goal is to evaluate...